rs33962676
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_000518.5(HBB):c.50G>A(p.Gly17Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000049 in 1,613,680 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another nucleotide change resulting in same amino acid change has been previously reported as Likely benignin UniProt. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G17R) has been classified as Likely benign.
Frequency
Consequence
NM_000518.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
HBB | NM_000518.5 | c.50G>A | p.Gly17Asp | missense_variant | 1/3 | ENST00000335295.4 | NP_000509.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HBB | ENST00000335295.4 | c.50G>A | p.Gly17Asp | missense_variant | 1/3 | 1 | NM_000518.5 | ENSP00000333994.3 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152184Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000239 AC: 6AN: 251228Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135766
GnomAD4 exome AF: 0.0000513 AC: 75AN: 1461496Hom.: 0 Cov.: 33 AF XY: 0.0000481 AC XY: 35AN XY: 727078
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152184Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74348
ClinVar
Submissions by phenotype
not provided Uncertain:3Benign:1
Benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 27, 2023 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jul 17, 2023 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jan 21, 2022 | Reported in combination with either hemoblobin S, hemoglobin C, or beta thalassemia trait, but limited clinical information is provided on these individuals (Baglioni and Weatherall, 1963; Huisman et al., 1978; Musumeci et al., 1979; Arribalzaga et al., 1996); Observed in the heterozygous state in a mother and daughter with abnormally low HbA1c levels (Gargallo et al., 2010); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Also described as Gly16Asp or Hb J-Baltimore using alternate nomenclature (Baglioni and Weatherall, 1963; Gargallo et al., 2010; Riou et al., 2015); This variant is associated with the following publications: (PMID: 27535164, 3808941, 14117783, 8226093, 5125343, 19429541, 31553106, 14092068, 511585, 24200101, 8745435, 19750260, 20206586, 25130136, 700140) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Nov 05, 2024 | The HBB c.50G>A (p.Gly17Asp) variant (also known as Hb J-Baltimore) has been reported in the heterozygous state in individuals with normal clinical presentation (HbVar (http://globin.cse.psu.edu/cgi-bin/hbvar/counter), and PMIDs: 26901597 (2015), 8745435 (1996), 8226093 (1993), 14117783 (1964)). Individuals who carry Hb J-Baltimore in combination with the Hb S (HBB c.20A>T, p.Glu7Val) or Hb C (HBB c.19G>A, p.Glu7Lys) pathogenic variant have clinical and hematological findings similar to carriers of Hb S or Hb C alone (PMID: 14117783 (1964)). Hb J-Baltimore is also reported to have normal stability (PMIDs: 8226093 (1993), 8745435 (1996)). The frequency of this variant in the general population, 0.000054 (7/129002 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 14, 2023 | Variant summary: HBB c.50G>A (p.Gly17Asp) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 4.9e-05 in 1613680 control chromosomes (gnomAD). This frequency is not significantly higher than estimated for a pathogenic variant in HBB causing Hemoglobinopathy (4.9e-05 vs 0.011), allowing no conclusion about variant significance. The variant, c.50G>A, has been reported in the literature in multiple compound heterozygotes carrying the variant of interest and HbS (e.g. Weatherall_1964, Baglioni_1963, Huisman_1978), and at least 3 of these individuals has been stated to have no symptoms suggestive of anemia or sickle-cell crisis during several years of follow up (Weatherall_1964). A functional study, which measured the rate of change of blood viscosity during deoxygenation demonstrated that blood from a compound heterozygote, behaved similarly to that of sickle-cell carriers, i.e. the variant didn't contribute to sickling (Weatherall_1964, Charache_1964). The variant also has been reported in at least 3 compound heterozygotes who carried a beta-thalassemia allele (Musumeci_1979, Arribalzaga_1996), these individuals had hematological parameters largely similar to individuals with beta-thalassemia trait. Functional studies performed on samples from two of these individuals, indicated normal oxyhemoglobin dissociation curves and P50 values, similar to thalassemia carriers (Arribalzaga_1996). Other functional studies noted no Heinz-body formation, or instability, in addition, oxygen affinity, Bohr-effect, and cooperativity, were all noted to be similar to normal (e.g. Musumeci_1979, Arribalzaga_1996). The following publications have been ascertained in the context of this evaluation (PMID: 8745435, 14092068, 14194270, 20206586, 19429541, 6859036, 700140, 16178917, 19750260, 5481775, 14282052, 3957922, 511585, 31553106, 17709689, 14117783). Three other clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as benign (n=1) ans VUS (n=2). Based on the evidence outlined above, the variant was classified as VUS-possibly benign. - |
HEMOGLOBIN J (BALTIMORE) Other:1
other, no assertion criteria provided | literature only | OMIM | Jan 01, 1979 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at